Contemporary OB/GYN week in review: IVF, cUTIs, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: IVF, cUTIs, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, February 19 - Friday, February 23, 2024), and click each link to read and watch anything you may have missed.
1.) Alabama Supreme Court ruling halts IVF treatment at UAB
Following a landmark decision regarding the status of embryos, the University of Alabama at Birmingham has suspended in vitro fertilization services, sparking concerns over reproductive rights and health care access as experts grapple with the legal aftermath.
Click here for the full article.
2.) FDA approves enmetazobactam for treatment of cUTIs
Enmetazobactam (Exblifep; Orchid Pharma) gains FDA approval for treating complicated urinary tract infections in adults after demonstrating superiority over piperacillin-tazobactam in clinical cure and microbiological eradication in a global phase 3 trial.
Click here for the full article.
3.) Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Click here for the full article.
4.) Study finds relugolix-CT Improves HMB in Black women
Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.
Click here for the full article.
5.) IVF deemed safe for obese women
Discover key findings from a comprehensive study on in vitro fertilization outcomes among women with obesity, shedding light on the importance of equitable access to fertility treatment regardless of body mass index.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More
